A Clinical Assay Named EvIPThT (RFT-623)

Invention Summary

Cancer detection methods traditionally rely on invasive procedures or single-marker assays that often yield false positives. This technology introduces a novel method for identifying tumor-derived extracellular vesicles (EVs) through antibody binding and beta-sheet structure analysis. The process involves: 1. Combining an antibody with a sample to form antigen-antibody complexes specific to tumor-derived EVs; 2. Exposing these EVs to a compound that binds to beta-sheet structures; 3. Assessing changes in binding to determine the presence of cancerous cells

Benefits

Noninvasive and minimally invasive cancer detection
High specificity and sensitivity in identifying cancerous EVs
Compatible with existing diagnostic and prognostic biomarkers to improve overall performance

Applications

Early Cancer Diagnosis
Disease Progression Monitoring and Treatment Response
Screening Option for High-Risk Populations

Patent

This technology has a U.S. Patent 2022/0349891 A1 pending and is available for licensing/partnering opportunities.

Contact

NDSU Research Foundation
info(at)ndsurf(dot)org
(701) 231-8173

NDSURF Tech Key

RFT, 623, RFT623

Inquire about this technology >